Computational Studies and Biosynthesis of Natural Products with Promising Anticancer Properties

Moumbock, Aurélien F. A.; Simoben, Conrad V.; Wessjohann, Ludger A.; Sippl, Wolfgang; Günther, Stefan; Ntie‐Kang, Fidele

doi:10.5772/67650

Cited by 5 publications

(3 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nowadays, computational methods that bridge the gap between the genomic and chemical space are instrumental in genomics-driven NP discovery ( 29–31 ). Within the framework of the ‘Genes to Metabolites’ approach, we hyperlinked streptomycetes strains to the SeMPI web server ( 32 ), a genome-based pipeline we developed, that leverages published genomic data to identify encoding biosynthetic gene clusters of isolated NPs and predicts the putative structures of related NPs that could be synthesized by polyketide synthases of type I ( 32 ), and nonribosomal peptide synthetases (unpublished data).…”

Section: Recent Developmentsmentioning

confidence: 99%

StreptomeDB 3.0: an updated compendium of streptomycetes natural products

Moumbock

Gao

Qaseem

et al. 2020

Nucleic Acids Research

View full text Add to dashboard Cite

Antimicrobial resistance is an emerging global health threat necessitating the rapid development of novel antimicrobials. Remarkably, the vast majority of currently available antibiotics are natural products (NPs) isolated from streptomycetes, soil-dwelling bacteria of the genus Streptomyces. However, there is still a huge reservoir of streptomycetes NPs which remains pharmaceutically untapped and a compendium thereof could serve as a source of inspiration for the rational design of novel antibiotics. Initially released in 2012, StreptomeDB (http://www.pharmbioinf.uni-freiburg.de/streptomedb) is the first and only public online database that enables the interactive phylogenetic exploration of streptomycetes and their isolated or mutasynthesized NPs. In this third release, there are substantial improvements over its forerunners, especially in terms of data content. For instance, about 2500 unique NPs were newly annotated through manual curation of about 1300 PubMed-indexed articles, published in the last five years since the second release. To increase interoperability, StreptomeDB entries were hyperlinked to several spectral, (bio)chemical and chemical vendor databases, and also to a genome-based NP prediction server. Moreover, predicted pharmacokinetic and toxicity profiles were added. Lastly, some recent real-world use cases of StreptomeDB are highlighted, to illustrate its applicability in life sciences.

show abstract

Section: Recent Developmentsmentioning

confidence: 99%

StreptomeDB 3.0: an updated compendium of streptomycetes natural products

Moumbock

Gao

Qaseem

et al. 2020

Nucleic Acids Research

View full text Add to dashboard Cite

show abstract

“…The development of drugs from marine sources is a highly tedious process, as it is difficult to procure and manufacture quantities of novel drug leads from marine sources [ 12 ]. For instance, the marine sponges are highly chemically versatile in nature and act as a resource of developmental compounds, such as hemiasterlin and discodermolide, which are extracted from primitive metals found in marine habitats.…”

Section: Introductionmentioning

confidence: 99%

Biotechnological Innovations from Ocean: Transpiring Role of Marine Drugs in Management of Chronic Disorders

et al. 2022

View full text Add to dashboard Cite

Marine drugs are abundant in number, comprise of a diverse range of structures with corresponding mechanisms of action, and hold promise for the discovery of new and better treatment approaches for the management of several chronic diseases. There are huge reserves of natural marine biological compounds, as 70 percent of the Earth is covered with oceans, indicating a diversity of chemical entities on the planet. The marine ecosystems are a rich source of bioactive products and have been explored for lead drug molecules that have proven to be novel therapeutic targets. Over the last 70 years, many structurally diverse drug products and their secondary metabolites have been isolated from marine sources. The drugs obtained from marine sources have displayed an exceptional potential in the management of a wide array of diseases, ranging from acute to chronic conditions. A beneficial role of marine drugs in human health has been recently proposed. The current review highlights various marine drugs and their compounds and role in the management of chronic diseases such as cancer, diabetes, neurodegenerative diseases, and cardiovascular disorders, which has led to the development of new drug treatment approaches.

show abstract

“…Since the earliest times, for the treatment of diseases, humans have heavily depended on medicinal plants whose “active principles” are secondary metabolites termed natural products (NPs). Precisely, NPs are “genetically encoded small molecules” originating from microorganisms, plants, or animals [1], [2]. They have better coverage of the biologically relevant chemical space (pharmacological space) than synthetic molecules.…”

Section: Introductionmentioning

confidence: 99%